CN101437505A - 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途 - Google Patents

去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途 Download PDF

Info

Publication number
CN101437505A
CN101437505A CNA2005800400639A CN200580040063A CN101437505A CN 101437505 A CN101437505 A CN 101437505A CN A2005800400639 A CNA2005800400639 A CN A2005800400639A CN 200580040063 A CN200580040063 A CN 200580040063A CN 101437505 A CN101437505 A CN 101437505A
Authority
CN
China
Prior art keywords
amino acid
use according
residue
acid residue
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800400639A
Other languages
English (en)
Chinese (zh)
Inventor
D·E·莫尔德
Y·C·李
张智全
R·C·C·黄
胡纪如
许铭华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN101437505A publication Critical patent/CN101437505A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800400639A 2004-10-06 2005-10-06 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途 Pending CN101437505A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61611404P 2004-10-06 2004-10-06
US60/616,114 2004-10-06

Publications (1)

Publication Number Publication Date
CN101437505A true CN101437505A (zh) 2009-05-20

Family

ID=36148866

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800400639A Pending CN101437505A (zh) 2004-10-06 2005-10-06 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途

Country Status (8)

Country Link
US (1) US20080207532A1 (https=)
EP (1) EP1848418A4 (https=)
JP (1) JP2008520548A (https=)
CN (1) CN101437505A (https=)
AU (1) AU2005294432A1 (https=)
CA (1) CA2583336A1 (https=)
MX (1) MX2007004025A (https=)
WO (1) WO2006041902A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640538A (zh) * 2012-02-03 2015-05-20 约翰霍普金斯大学 包含ndga衍生物和索拉非尼的组合物以及其在治疗癌症中的用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057265B1 (en) * 2006-08-28 2016-03-23 The Ohio State University Research Foundation Compositions for reducing cell adhesion to bubbles
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
JP5832721B2 (ja) 2007-03-14 2015-12-16 バイオンシル・エス．アール．エル．Ｂｉｏｎｓｉｌ Ｓ．Ｒ．Ｌ． 上皮腫瘍細胞における薬剤耐性のモジュレータ化合物
EP2240168B1 (en) * 2008-01-08 2014-05-14 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
EP2538935B1 (en) 2010-02-22 2014-11-05 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
EP2699237A4 (en) * 2011-04-21 2014-11-12 Childrens Hosp Medical Center THERAPY FOR LEUKEMIA
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
WO2012166778A2 (en) * 2011-05-31 2012-12-06 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
JP6255038B2 (ja) * 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
GB201307989D0 (en) * 2013-05-02 2013-06-12 Helperby Therapeutics Ltd Novel combinations and use
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
CN105902526A (zh) * 2016-05-06 2016-08-31 兰州大学 马索罗酚在制备治疗包虫病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003800A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640538A (zh) * 2012-02-03 2015-05-20 约翰霍普金斯大学 包含ndga衍生物和索拉非尼的组合物以及其在治疗癌症中的用途
CN104640538B (zh) * 2012-02-03 2018-01-02 约翰霍普金斯大学 包含ndga 衍生物和索拉非尼的组合物以及其在治疗癌症中的用途

Also Published As

Publication number Publication date
CA2583336A1 (en) 2006-04-20
EP1848418A2 (en) 2007-10-31
EP1848418A4 (en) 2010-09-08
AU2005294432A1 (en) 2006-04-20
JP2008520548A (ja) 2008-06-19
WO2006041902A3 (en) 2009-04-16
WO2006041902A2 (en) 2006-04-20
MX2007004025A (es) 2007-06-11
US20080207532A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
US6294546B1 (en) Uses of diterpenoid triepoxides as an anti-proliferative agent
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
CN101437505A (zh) 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途
US8691870B2 (en) Use of isothiocyanates for treating cancer
JP2018535244A (ja) 関節疾患及び皮膚疾患の治療のためのラパマイシンとメトホルミンの併用
JPH10509741A (ja) 医薬の経口生体利用率を増加させるための方法、組成物およびキット
JP2005509599A (ja) 抗癌組み合わせ
Mihailidou et al. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models
JP5440985B2 (ja) メラノーマの治療
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2009536956A (ja) 抗癌治療法
JP2015214579A (ja) 癌細胞アポトーシス
JP2006513223A (ja) ｐ−アミノ安息香酸（ＰＡＢＡ）によるメラニン形成及びメラノーマ転移の阻害
FR3056108A1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif
CN108524533A (zh) 一种化合物用作抗肿瘤药物增效剂和逆转剂
WO2014029016A1 (en) Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer
CN101346137A (zh) 含有孔布勒塔斯塔坦与抗癌剂的组合物
WO2006009893A2 (en) Cancer chemotherapy
WO2007005760A1 (en) Methods of application of chemical compounds having therapeutic activities in treating cancers
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
BG107806A (bg) Състав, включващ камптотецинови и стилбенови производни, за лечение на рак
HK1131740A (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
EP4463147A1 (en) Methods for treating pancreatic cancer
GB2504550A (en) Diarylurea compound PQ401 for inhibiting the growth and/or proliferation of cancer stem cells
Chatterji et al. Microtubules as Anti-Cancer Drug Targets

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131740

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090520

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1131740

Country of ref document: HK